OccuLogix completes SOLX acquisition

Toronto-OccuLogix Inc. and SOLX Inc. merged in September, with SOLX becoming a wholly owned subsidiary of OccuLogix. Doug Adams, former president and chief executive officer of SOLX, is now president of the subsidiary.

Toronto-OccuLogix Inc. and SOLX Inc. merged in September, with SOLX becoming a wholly owned subsidiary of OccuLogix. Doug Adams, former president and chief executive officer of SOLX, is now president of the subsidiary.

Based at the Boston University Photonics Center, SOLX developed the DeepLight Glaucoma Treatment System, including the DeepLight 790 Titanium Sapphire Laser and the DeepLight Gold Micro-Shunt, which can be used together or separately to reduce IOP. The system components have received international CE approval and are being studied in two randomized, multicenter trials in the United States.